Chimerical Antigen Receptor
Showing 1 - 25 of >10,000
CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study
Not yet recruiting
- Lymphoma
- Chimeric Antigen Receptor
- (no location specified)
Oct 24, 2023
Neuroblastoma Trial (GD2 CAR T cells)
Not yet recruiting
- Neuroblastoma
- GD2 CAR T cells
- (no location specified)
Aug 5, 2023
Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T
Not yet recruiting
- Recurrent Glioblastoma
- Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
- (no location specified)
Apr 4, 2023
Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Neuroblastoma
- GINAKIT Cells
- +2 more
-
Houston, TexasTexas Children's Hospital
Jan 18, 2023
19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)
Recruiting
- 19 and 22+ B Cell Hematologic Tumors
- 19 and 20+ B Cell Hematologic Tumors
- Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
-
Wuhan, Hubei, ChinaTongji Hospital
Jan 11, 2023
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 4, 2023
Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,
Not yet recruiting
- Kidney Transplant
- +2 more
- Cyclophosphamide
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 20, 2023
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,
Recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Manufactured Anti-BCMA CAR-T cells
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 6, 2023
Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)
Not yet recruiting
- Small Cell Lung Cancer Extensive Stage
- Large Cell Neuroendocrine Carcinoma of the Lung
- LB2102
- (no location specified)
Jan 10, 2023
Advanced Sarcoma Trial (NKG2D-CAR memory T cell)
Not yet recruiting
- Advanced Sarcoma
- NKG2D-CAR memory T cell
- (no location specified)
Oct 17, 2023
Study of Participants Who ReceivedAllogeneic CAR T-Cell Product
Recruiting
- Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
-
Culver City, CaliforniaScience 37, Inc.
Apr 10, 2023
Colorectal Cancer, Esophagus Cancer, Gastric Cancer Trial in Hangzhou (CEA-targeted CAR-T cells)
Recruiting
- Colorectal Cancer
- +6 more
- CEA-targeted CAR-T cells
-
Hangzhou, Zhejiang, China
- +1 more
Sep 18, 2023
Solid Tumor Trial (HER2-E-CART cells)
Not yet recruiting
- Solid Tumor
- HER2-E-CART cells
- (no location specified)
Feb 16, 2023
Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)
Not yet recruiting
- Neuroendocrine Tumor (NET)
- Colorectal Cancer (CRC)
- CHM-2101 CAR-T cells
- (no location specified)
Sep 20, 2023
Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)
Recruiting
- Gastric Cancer
- +6 more
- CEA-targeted CAR-T cells
-
Taiyuan, Shanxi, China
- +1 more
Aug 24, 2023
B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)
Recruiting
- B-Cell Lymphoma
- +4 more
- 19(T2)28z1xx TRAC T cell
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023
Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))
Not yet recruiting
- Multiple Myeloma
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Jan 13, 2023
Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)
Recruiting
- Gastric Cancer
- +7 more
- CEA-targeted CAR-T cells
-
Wuhu, Anhui, ChinaThe First Affiliated Hospital of Wannan Medical College
Nov 9, 2023
Lymphoma, Leukemia, Plasma Cell Dyscrasia Trial in San Francisco (Web Application)
Not yet recruiting
- Lymphoma
- +2 more
- Web Application
-
San Francisco, CaliforniaUniversity of California, San Francisco
Oct 4, 2022
Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)
Not yet recruiting
- Follicular Lymphoma
- Axicabtagene Ciloleucel
- +5 more
- (no location specified)
Sep 21, 2023
Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer Trial (LB1908)
Not yet recruiting
- Gastric Cancer
- +3 more
- LB1908
- (no location specified)
Sep 9, 2022
SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)
Not yet recruiting
- SLE (Systemic Lupus)
- CAR T-cell therapy
-
Bangkok, Please Select, ThailandKing Chulalongkorn Memorial Hospital
Nov 23, 2023